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A Ab bs st tr ra ac ct t
The availability of personalized genomic tests, ordered directly by consumers, is rapidly growing.
These tests are unlike other genetic or biochemical tests in the sheer amount of data they
provide, but interpretation of these genome-wide analyses for health remains uncertain because
of the lack of information about environmental and other factors, and because for the vast
majority of genetic loci the associations with disease are weak. Although these tests could
provide value to customers by offering tools for social networking or genealogy, there are
questions about whether and how to regulate these tests and about the extent to which they
provide medical information.
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I In nt tr ro od du uc ct ti io on n
A new era in commercial, personalized genomics was
heralded when several companies in the United States,
including 23andMe, deCODEme, SeqWright and Navigenics,
began offering ‘direct-to-consumer’ genomic testing [1].
Some companies test genetic risk for specific diseases, for
example Smart Genetics’ service for Alzheimer’s disease.
Other companies offer advice on the basis of genetic risk
factors and then provide nutritional and other supplements.
Early adopters, including some journalists who reported on
their own experiences getting these tests, favorably
described ‘discovering’ risk factors that they should be
concerned about and the feeling of relief about being
unaffected by other factors [2-4]. One author discussed his
family history of heart disease and the realization, thanks to
23andMe, that his genes made him less likely than average
to have heart disease [2]. But was his interpretation of the
test results correct? Family history captures information
about inherited risks in a particular family, whereas
genome-wide association studies identify population
averages and thus generally give a less accurate assessment
of risk than is given by family history. How personal are
personal genomics tests, and is the validity of these tests
good enough for them to be ready for general use by
consumers to inform medical decisions? And, given the
complexity of genomic information and the potential for
misinterpretation, how, if at all, should this kind of direct-
to-consumer testing be regulated?
D Di is sc cu us ss si io on n
Federal regulation of genetic tests in the US is minimal,
being largely confined to approval by the Food and Drug
Administration (FDA) of test kits and very complex multi-
gene indicators, as well as quality control of laboratories
performing tests that are used “to assess patient health and
inform medical decisions” through the Clinical Laboratory
Improvement Amendments (CLIA). Proficiency testing
required by CLIA does not include standards specific to
DNA-based genetic tests [5,6]. Most laboratory tests, as
opposed to home-testing kits (for HIV or pregnancy, for
example), are not specifically regulated.
The Secretary’s Advisory Committee on Genetics, Health &
Society, which advises the US Department of Health and
Human Services, has identified significant gaps in theoversight and enforcement of genetic testing, especially
nutrigenomic and direct-to-consumer tests [6]. Some state
agencies have stepped into the gap, including California and
New York. The California Department of Public Health
recently sent ‘cease and desist’ letters to 13 genetic testing
companies to prevent the sale of personal genomics tests to
state residents [7]. New York sent similar letters to 23 firms
in spring 2008 [8]. The California Department insists that
these companies comply with state law that requires a
license to perform clinical laboratory tests and prohibits
offering genetic tests directly to consumers without a
physician’s order. California state law addresses genetic
testing to ensure that test results are accurate and valid and
offered only with sufficient medical oversight to avoid
unnecessary harm. The Department seems to be well within
the bounds of its statutory authority, as personal genomics
services clearly fit the statutory definitions of a genetic test.
The companies who received the letters from the California
Department of Public Health have offered at least three
arguments in their public responses. The arguments range,
in our opinion, from weak to indefensible. One argument is
that genetic information is “a fundamental part of you” and
that people have a right to it. This is fair enough; but the
same argument could apply to any test about someone’s
body. Clinical tests are regulated for a reason: the
information that they provide is not worth having if it is not
accurate and valid, which is why licenses are required for
those who provide it. People may indeed have a right to their
genetic information, but it does not follow that we should
not regulate the process to make sure that information is
appropriately provided.
A second argument used is that this testing is not really
medical. According to a quote in the New York Times from
Mari Baker, Navigenics’ chief executive: “It doesn’t say you
have a disease… It says you carry a genetic predisposition for
the disease and should talk with a health care professional”
[7]. If that is true, cholesterol tests, lipid panels and glucose
tests are not ‘medical testing’ either, because they merely
measure risk factors, not actual disease. Moreover, the
marketing of personal genomics tests makes it clear that it is
precisely the health (and therefore medical) value of the
information that drives demand. Not all of the information
provided by these companies is medical, but as long as even
some of it is, the law pertains. Mari Baker’s point that her
clients should talk to a health professional [7] represents the
very reason that California and New York passed their laws,
except that the laws mandate professional engagement from
the start, not after the test has already been done.
A third argument put forward by the testing companies is
that patients deserve direct access to their health infor-
mation without a physician intermediary. Some of the
companies clearly have no physician involved in ordering the
tests. At least one company claims to be in compliance with
the law because a company physician reviews all customer
orders. This response is clearly not sufficient. The point of
the law is to ensure that each patient (or customer) has a
physician looking after their interests when ordering
medical tests, to advise on the need for, interpretation of,
and clinical follow-up after the tests. A physician working for
a company selling the tests is clearly not well situated to look
after a patient’s best interest.
One of the problems with offering genome-wide data is that
most of the growing information derived from association
studies has very little predictive power. Typical odds ratios
found in genome-wide association studies are less than 1.5
[9]. A 50% increased risk may sound like a lot until you
realize how low the starting odds usually are. The combined
effect of all 20 genetic variants associated with adult height
in a recent study explained only 3% of height variation [10].
Another variant increased the risk of coronary artery disease
from 1% to 1.6% [11-13]. The reporter who thinks his genes
do not predispose him to heart disease has failed to
understand how little these tests tell him [14]. To make
matters more confusing, personal genomics could predict
risks of very weak genetic associations while leaving out
powerful predictive mutations. Genetic tests for well
understood heritable diseases can detect powerful causal
effects (for example, some inherited breast cancer genes that
account for 5% of breast cancer in younger women). But
these are not the tests offered through personal genomics
services. In rare high-risk families, tests for specific
mutations are needed. Personal genomics services in such
families are likely to be downright misleading.
Until there is federal regulation or oversight, the California
and New York states are right to create standards to protect
their citizens from the risks of medical testing. Initial
experience of individuals, as exemplified by reporters’ experi-
ences with current-generation personal genomics services,
makes it clear that the information is likely to be mis-
understood without the direct guidance of a physician. And
they might not get much help even there. Most physicians
know little about the studies that the new personal genomics
services use to make their predictions; a lot more education
of the medical community therefore also needs to take place.
Regulation of genetic tests must take into account the
challenges of predicting complex traits. The FDA is seeking
to address concerns about the difficulty of validating some
highly complex genetic tests whose results are not trans-
parent to clinicians. The FDA issued guidance on in vitro
diagnostic multivariate index assays (IVDMIAs) that are
“based on observed correlations between multivariate data
and clinical outcome” [15]. There is only a thin line between
those tests, over which FDA has asserted jurisdiction, and
the personal genomics services being offered directly to
consumers. FDA has defined an IVDMIA as: “a device that:
(1) Combines the values of multiple variables using an
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(e.g., a ‘classification,’ ‘score,’ ‘index,’ etc.), that is intended for
use in the diagnosis of disease or other conditions, or in the
cure, mitigation, treatment or prevention of disease, and (2)
Provides a result whose derivation is non-transparent and
cannot be independently derived or verified by the end user”
[15]. Personal genomics services do not produce a single index
number. Instead they provide hundreds of thousands of data
points and hundreds of risk evaluations. Which is more
confusing, more prone to misinterpretation or more in need of
professional interpretation?
C Co on nc cl lu us si io on ns s
The advent of personal genomics testing will not cleanly fit
the regulatory model for Mendelian genetic tests, nor perhaps
even the regulatory model for medical tests generally. We
must move beyond a purely medical model to truly evaluate
the risks and benefits. Clearly these tests are being marketed
not only for health risk information but also for genealogy,
studying ancestry and as tools for social networking. Some
information might be used for forensic purposes. To
maximize the benefits and minimize the harms of whole-
genome analysis, we need to view this technology in a much
broader way. Yet although the standard medical model might
not prove to be the way in which we ultimately choose to
regulate and monitor these services, it is what we have, and it
is where we will start. New York and California have state
laws that govern medical tests, and the health information in
personal genomics services meets their definitions. It would
surely be better to develop a coherent national framework
suited to the full range of information coming from these
services. Indeed, a unified international framework is
necessary, given easy access to these services across borders
via the internet. However, we will not get the ideal regulatory
system by pretending this is not medical information or
hoping that oversight and regulation are unnecessary.
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